Entrada Therapeutics Employee Directory
Biotechnology ResearchMassachusetts, United States201-500 Employees
Entrada Therapeutics is a Boston-based biotechnology company focused on developing genetic medicines capable of engaging intracellular targets that have historically been difficult to reach. Through proprietary, modular approaches, it is assembling a development portfolio aimed at neuromuscular and inherited retinal diseases, among other conditions. The firm’s lead programs include strategies to address Duchenne muscular dystrophy by exon skipping, reflecting its focus on intracellular genetic modulation. Based in Boston, Massachusetts, the company operates as a clinical-stage biopharmaceutical firm addressing unmet needs in genetic diseases with limited treatment options. In 2026, Entrada announced progress on VX-670, a clinical-stage program for myotonic dystrophy type 1 that is being developed through a partnership.